In vivo treatment with IL-1 reduces the severity and duration of antigen-induced arthritis in rats.
IL-1 has been implicated in the pathogenesis of arthritis. Although IL-1 injected in vivo into normal joints results in a transient inflammatory reaction, we have shown that three weekly repetitive injections of IL-1 do not produce a progressive inflammatory condition suggestive of chronic arthritis. In fact, priming normal joints with three weekly IL-1 intraarticular injections results in a significant reduction in joint swelling and diminished histopathologic alterations/lesions caused by subsequent methylated BSA-induced arthritis. Similarly, post treatment with IL-1 intraarticular injection after arthritis induction reduced arthritic swelling and joint injury if IL-1 was given during the developing stage of arthritis. Our results suggest that IL-1 might limit arthritic inflammation and progressive cartilage destruction through an, as yet, undetermined mechanism(s). Further in vivo investigations are required to determine the therapeutic utility of IL-1 in reducing early arthritic inflammation.
Jacobs
C
C
Department of Cellular Immunology, Immunex Corporation, Seattle, WA 98101.
Young
D
D
Tyler
S
S
Callis
G
G
Gillis
S
S
Conlon
P J
PJ
D000818:Animals; D000941:Antigens; D001168:Arthritis / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D004334:Drug Administration Schedule; D005260:Female; D007270:Injections, Intra-Articular; D007375:Interleukin-1 / Q000008:administration & dosage* / Q000627:therapeutic use; D007719:Knee Joint / Q000000981:diagnostic imaging / Q000473:pathology; D011292:Premedication; D011859:Radiography; D051381:Rats; D011917:Rats, Inbred Lew; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use; D012710:Serum Albumin, Bovine; D013997:Time Factors
D000941:Antigens; D007375:Interleukin-1; D011994:Recombinant Proteins; C029180:methylated bovine serum albumin; D012710:Serum Albumin, Bovine